KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has appointed Doug Ulman, President and CEO of LIVESTRONG, to its Corporate Advisory Board.
Mr. Ulman, age 34, created the LIVESTRONG Young Adult Alliance. Before his involvement with and leadership of LIVESTRONG, Ulman founded the Ulman Cancer Fund for Young Adults, a non-profit organization that provides support, education, and resources for young adults battling the disease. He joined LIVESTRONG in 2001 as its director of survivorship, and was appointed President and CEO in 2007. Mr. Ulman, a cancer survivor and survivorship advocate, has received several awards for his leadership in the fight against cancer, as well as his acclaimed contributions to community service. In 2005, he was honored by both the American Psychosocial Oncology Society and the Association of Oncology Social Workers, and in 2009 and 2010, Ulman was named to the Non-Profit Times Power and Influence Top 50, a tribute given to the top 50 Non-profit executives. He holds many civic and charitable board positions, and recently completed serving a four-year term as the Chairman of the National Cancer Institute Director’s Consumer Liaison Group.
Additionally, Mr. Ulman has been featured nationally through America’s leading media and news channels, including CNN, ABC News, NBC Nightly News, The New York Times, The Wall Street Journal, and The Washington Post. He has also made appearances at colleges, universities, corporations and civic organizations in order to spread LIVESTRONG’s message and raise awareness of cancer.
Mr. Ulman said, “I am honored to join Provectus’s Corporate Advisory Board, and I look forward to using my personal cancer and cancer advocacy experiences to help Provectus continue to push patient centered care forward. My personal experience with melanoma gives me a unique perspective on the needs of individuals and families who are facing this disease. By providing awareness and guidance to Provectus as it develops its therapies and ongoing corporate strategies, I also expect to further the fight to help those who are, unfortunately, still fighting.”
Dr. Craig Dees, Ph.D., CEO of Provectus said, "We are thrilled to welcome Mr. Ulman to our Corporate Advisory Board and look forward to his contributions to the Board and the Company’s strategy. Doug’s appointment marks another step in the transition of Provectus’s efforts to increase visibility and awareness. We are optimistic that Doug’s background in business, oncology and social work will help provide Provectus with public relations and patient advocacy assistance as we continue to develop our cancer and dermatological therapies as well as our corporate strategies.”
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.